# US 2003/0216464 A1 · Novel herbal chemical composition for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216464 A1
- Document ID: US20030216464A1
- Status: Published application
- Kind: A1
- Application number: 10/463,060
- Filed: 2003-06-17
- Published: 2003-11-20
- Earliest claimed: 2001-12-07
- Assignees: Council of Scientific and Industrial Research
- Inventors: Janaswamy Madhusudana Rao; Pullela Venkata Srinivas; Jhillu Singh Yadav; Kondapuram Vijaya Raghavan; A.K. Saxena; M. Shanmugavel; Himani Kampasi; Gulam Nabi Qazi
- Web page: https://patentgrep.com/patent/US20030216464A1

## CPC

- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 36/13: Coniferophyta (gymnosperms)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relate to a novel synergistic composition of lignans exhibiting anticancer activities for breast, cervix, neuroblastoma, colon, liver, lung, mouth, ovary and prostate cancer obtained from the plant extract of Cedrus deodra, said composition comprising of (−)-Matairesinol in the range of 9 to 13% by weight, (−)-Wikstromol in the range of 75 to 79% by weight, Dibenzylbutyrolactol in the range of 7 to 11% by weight, and Unidentified material in the range of 2.6 to 3% by weight; further, the synergistic composition of lignan is used in combination with pharmaceutically acceptable carriers for inhibiting growth of various human cancer cell lines selected from breast, cervix, neuroblastoma, colon, liver, lung, mouth, ovary and prostate tissues.

## Claims

### Claim 1

A novel synergistic composition of lignans exhibiting anticancer activities for breast, cervix, neuroblastoma, colon, liver, lung, mouth, ovary and prostate cancer obtained from the plant extract of Cedrus deodra, said composition comprising
(a) (−)-Matairesinol in the range of 9 to 13% by weight,
(b) (−)-Wikstromol in the range of 75 to 79% by weight,
(c) Dibenzylbutyrolactol in the range of 7 to 11% by weight, and
(d) Unidentified material in the range of 2.6 to 3% by weight,

### Claim 2 (depends on 1)

The composition as claimed in claim 1, wherein the synergistic lignan composition inhibits the growth of cancer cells of breast up to 80% at a concentration ranging from 30-100 μg/ml.

### Claim 3 (depends on 2)

The composition as claimed in claim 2, wherein the breast cell line is selected from group consisting of MCF-7 and T-47-D.

### Claim 4 (depends on 1)

The composition as claimed in claim 1, wherein the synergistic lignan composition inhibits the growth of cancer cells of cervix up to 89% at a at a concentration ranging from 30-100 μg/ml.

### Claim 5 (depends on 4)

The composition as claimed in claim 4, wherein the cervix cell line is selected from the group consisting of Hela and SiHa.

### Claim 6 (depends on 1)

The composition as claimed in claim 1, wherein the synergistic lignan composition inhibits the growth of cancer cells of neuroblastoma up to 96% at a concentration ranging from 30-100 μg/ml.

### Claim 7 (depends on 6)

The composition as claimed in claim 6, wherein cancer cell line of neuroblastoma is selected from the group consisting of SF-539, SKNMC, IMR-32, SKNSH and SNB-78.

### Claim 8 (depends on 1)

The composition as claimed in claim 1, wherein the synergistic lignan composition inhibits the growth of cancer cells of colon up to 97% at a concentration ranging from 30-100 μg/ml.

### Claim 9 (depends on 8)

The composition as claimed in claim 8, wherein cancer cell line of colon is selected from the group consisting of Colo-205, HCT-15, HT-29 and SW-620.

### Claim 10 (depends on 1)

The composition as claimed in claim 1, wherein the synergistic lignan composition inhibits the growth of cancer cells of liver up to 73% at a concentration ranging from 30-100 μg/ml.

### Claim 11 (depends on 10)

The composition as claimed in claim 10, wherein the cancer cell line of liver is selected from the group consisting of Hep-2 and Hep-G-2.

### Claim 12 (depends on 1)

The composition as claimed in claim 1, wherein the synergistic lignan composition inhibits the growth of cancer cells of lung up to 83% at a concentration ranging from 30-100 μg/ml.

### Claim 13 (depends on 12)

The composition as claimed in claim 12, wherein the cancer cell line of lung is selected from the group consisting of A-549, NC1-H23 and HOP-18.

### Claim 14 (depends on 1)

The composition as claimed in claim 1, wherein the synergistic lignan composition inhibits the growth of cancer cells of mouth up to 100% at a concentration ranging from 30-100 μg/ml.

### Claim 15 (depends on 14)

The composition as claimed in claim 14, wherein the cancer cell line of mouth is KB.

### Claim 16 (depends on 1)

The composition as claimed in claim 1, wherein the synergistic lignan composition inhibits the growth of cancer cells of ovary up to 96% at a concentration ranging from 30-100 μg/ml.

### Claim 17 (depends on 16)

The composition as claimed in claim 16, wherein the cancer cell line of ovary is selected from the group consisting of OVCAR-5, NIH-OVCAR-3 and SK-OV-3.

### Claim 18 (depends on 1)

The composition as claimed in claim 1, wherein the synergistic lignan composition inhibits the growth of cancer cells of prostrate up to 98% at a concentration of ranging from 30-100 μg/ml.

### Claim 19 (depends on 18)

The composition as claimed in claim 18, wherein the cancer cell line of prostrate is selected from the group consisting of DU-145 and PC-3.

### Claim 20 (depends on 1)

The composition as claimed in claim 1, wherein the synergistic composition of lignan is administered to the patient in combination with a pharmaceutically acceptable additive, carrier, diluent, solvent, filter, lubricant, excipient, binder, or stabilizer.

### Claim 21 (depends on 1)

The composition as claimed in claim 1, wherein synergistic lignan composition can be administered systemically and/or orally or any other suitable method.

### Claim 22 (depends on 1)

The composition as claimed in claim 1, wherein the subjects are selected from animals or mammals preferably humans.

### Claim 23

A composition exhibiting anti cancer activities for cancer cell lines selected mainly from the group consisting breast, cervix, neuroblastoma, colon, liver and lung, said composition comprising pharmaceutically effective dosage of (−)-wikstromol or a formulation containing (−)-wikstromol.

### Claim 24 (depends on 23)

The composition as claimed in claim 23, wherein the cancer cell line used are selected from group consisting breast cells MCF-7 and ZR-75-1; cervix cell SiHa; neuroblastoma cells SKNMC and IMR-32; colon cells colo-205HT-29 and SW-620; liver cell Hep-2; and lung cell A-549.

### Claim 25 (depends on 23)

The composition as claimed in claim 23, wherein (−)-wikstromol inhibits the growth of cancer cells of breast up to 51% at a concentration of about 100 μg/ml.

### Claim 26 (depends on 23)

The composition as claimed in claim 23, wherein (−)-wikstromol inhibits the growth of cancer cells of cervix up to 37% at a concentration of about 100 μg/ml.

### Claim 27 (depends on 23)

The composition as claimed in claim 23, wherein (−)-wikstromol inhibits the growth of cancer cells of neuroblastoma up to 56% at a concentration of about 100 μg/ml.

### Claim 28 (depends on 23)

The composition as claimed in claim 23, wherein (−)-wikstromol inhibits the growth of cancer cells of colon up to 67% at a concentration of about 100 μg/ml.

### Claim 29 (depends on 23)

The composition as claimed in claim 23, wherein (−)-wikstromol inhibits the growth of cancer cells of liver up to 46% at a concentration of about 100 μg/ml.

### Claim 30 (depends on 23)

The composition as claimed in claim 23, wherein (−)-wikstromol inhibits the growth of cancer cells of lung up to 56% at a concentration of about 100 μg/ml.

### Claim 31 (depends on 23)

The composition as claimed in claim 23, wherein the (−)-wikstromol is administered in combination with a pharmaceutically acceptable carriers, additives, diluents, solvents, filters, lubricants, excipients, binders and stabilizers.

### Claim 32 (depends on 23)

The composition as claimed in claim 23, can be administered systematically and/or orally or any other suitable method.

### Claim 33 (depends on 23)

The composition as claimed in claim 23, wherein the subjects are selected from animals or mammals preferably humans.

### Claim 34

A composition exhibiting anti cancer activities for cancer cell lines selected mainly from the group consisting breast, cervix, neuroblastoma, colon, liver and lung, , said composition comprising a pharmaceutically effective dosage of (−)-Matairesinol or a formulation containing (−)-Matairesinol.

### Claim 35 (depends on 34)

The composition as claimed in claim 34, wherein the cancer cell lines used are selected from the group comprising of breast cells MCF-7 and ZR-75-1; cervix cell SiHa; neuroblastoma cells SKNMC and IMR-32; colon cells Colo-205, HT-29 and SW-620; liver cell Hep-2; and lung cell A-549.

### Claim 36 (depends on 34)

The composition as claimed in claim 34, wherein (−)-Matairesinol inhibits the growth of cancer cells of breast up to 62% at a concentration of about 100 μg/ml

### Claim 37 (depends on 34)

The composition as claimed in claim 34, wherein (−)-Matairesinol inhibits the growth of cancer cells of cervix up to 63% at a concentration of about 100 μg/ml

### Claim 38 (depends on 34)

The composition as claimed in claim 34, wherein (−)-Matairesinol inhibits the growth of cancer cells of neuroblastoma up to 77% at a concentration of about 100 μg/ml

### Claim 39 (depends on 34)

The composition as claimed in claim 34, wherein (−)-Matairesinol inhibits the growth of cancer cells of colon up to 93% at a concentration of about 100 μg/ml

### Claim 40 (depends on 34)

The composition as claimed in claim 34, wherein (−)-Matairesinol inhibits the growth of cancer cells of liver up to 64% at a concentration of about 100 μg/ml

### Claim 41 (depends on 34)

The composition as claimed in claim 34, wherein (−)-Matairesinol inhibits the growth of cancer cells of lung up to 65% at a concentration of about 100 μg/ml

### Claim 42 (depends on 34)

The composition as claimed in claim 34, wherein the (−)-Matairesinol is administered to the patient in combination with a pharmaceutically acceptable carriers additives, diluents, solvents, filters, lubricants, excipients, binders and stabilizers.

### Claim 43 (depends on 34)

The composition as claimed in claim 34, wherein (−)-Matairesinol may be administered systematically or orally.

### Claim 44 (depends on 34)

The composition as claimed in claim 34, wherein the subjects are selected from animals or mammals preferably humans

### Claim 45 (depends on 1)

Process for isolation of synergistic lignan composition as claimed in claim 1 from the plant extract of Cedrus deodra comprises steps of:
(a) powdering the plant Cedrus deodra,
(b) extracting the powdered plant in a soxhlet apparatus successively with hydrocarbon solvent followed by halogenated solvent,
(c) concentrating the extract of hydrocarbon solvent and halogenated solvent separately, and
(d) purifying halogenated solvent extract by chromatography on an adsorbent by eluting with mixture of organic solvents to yield (−)-Matairesinol 1 to 2% by weight, (−)-Wikstromol 10 to 14% by weight, Dibenzylbutyrolactol 1 to 2% by weight and unidentified material 0.2 to 0.3% by weight with respect to extract and which together constitute as synergistic lignan composition.

### Claim 46 (depends on 45)

A process as claimed in claim 45 in step (a) wherein the plant part is wood.

### Claim 47 (depends on 45)

A process as claimed in claim 45 in step (b) wherein the hydrocarbon solvent is selected from group consisting of hexane and petroleum ether, preferably hexane.

### Claim 48 (depends on 45)

A process as claimed in claim 45 wherein, the halogenated solvent is selected from group consisting carbon tetrachloride, methylene chloride or chloroform, preferably chloroform.

### Claim 49 (depends on 45)

A process as claimed in claim 45 in step (c) wherein, the extracts are concentrated under vacuum.

### Claim 50 (depends on 45)

A process as claimed in claim 45 in step (d) the purification is carried out using silica gel as an adsorbent and eluting with different proportions of chloroform-methanol mixture to get pure compounds (−)-wikstromol, (−)-metairesinol, dibenzylbutyrolactol, an unidentified material and which together constitute as synergistic lignan composition.

### Claim 51

A method of treating a patient with cancer mainly breast, cervix, neuroblastoma, colon, liver, lung, mouth, ovary and prostate, said method comprising administering a pharmaceutically effective dosage of synergistic composition of lignan composition to the patient.

### Claim 52 (depends on 51)

A method as claimed in claim 51, wherein the synergistic lignan composition used in combination with pharmaceutically acceptable carriers.

### Claim 53 (depends on 51)

A method as claimed in claim 51, wherein synergistic lignan composition may be administered systemically and/or orally or any other suitable method.

### Claim 54 (depends on 51)

A method as claimed in claim 51, wherein the subjects are selected from animals or mammals preferably humans.

### Claim 55 (depends on 51)

A method as claimed in claim 51, wherein the said synergistic lignan composition inhibits the growth of cancel cells of breast up to 80% at a concentration ranging from 30-100 μg/ml.

### Claim 56 (depends on 55)

A method as claimed in claim 55, the breast cell lines inhibited are MCF-7 and T-47-D.

### Claim 57 (depends on 51)

A method as claimed in claim 51, wherein the said synergistic lignan composition inhibits the growth of cancel cells of cervix up to 81% at a concentration ranging from 30-100 μg/ml.

### Claim 58 (depends on 57)

A method as claimed in claim 57, the cervix cell lines inhibited are Hela and SiHa.

### Claim 59 (depends on 51)

A method as claimed in claim 51, wherein the said synergistic lignan composition inhibits the growth of cancel cells of neuroblastoma up to 92% at a concentration ranging from 30-100 μg/ml.

### Claim 60 (depends on 59)

A method as claimed in claim 59, the neuroblastoma cell lines inhibited are SF-539, SKNMC, IMR-32, SKNSH and SNB-78.

### Claim 61 (depends on 51)

A method as claimed in claim 51, wherein the said synergistic lignan composition inhibits the growth of cancel cells of colon up to 95% at a concentration ranging from 30-100 μg/ml.

### Claim 62 (depends on 61)

A method as claimed in claim 61, the colon cell lines inhibited are Colo-205, HCT-15, HT-29 and SW-620.

### Claim 63 (depends on 51)

A method as claimed in claim 51, wherein the said synergistic lignan composition inhibits the growth of cancel cells of liver up to 73% at a concentration ranging from 30-100 μg/ml.

### Claim 64 (depends on 63)

A method as claimed in claim 63, the liver cell line inhibited is Hep-2.

### Claim 65 (depends on 51)

A method as claimed in claim 51, wherein the said synergistic lignan composition inhibits the growth of cancel cells of lung up to 92% at a concentration ranging from 30-100 μg/ml.

### Claim 66 (depends on 65)

A method as claimed in claim 65, the lung cell lines inhibited are A-549 and NCI-H23.

### Claim 67 (depends on 51)

A method as claimed in claim 51, wherein the said synergistic lignan composition inhibits the growth of cancel cells of mouth up to 99% at a concentration ranging from 30-100 μg/ml.

### Claim 68 (depends on 67)

A method as claimed in claim 67, the mouth cell line inhibited is KB

### Claim 69 (depends on 51)

A method as claimed in claim 51, wherein the said synergistic lignan composition inhibits the growth of cancel cells of ovary up to 96% at a concentration ranging from 30-100 μg/ml.

### Claim 70 (depends on 69)

A method as claimed in claim 69, the ovary cell lines inhibited are OVCAR5 and SK-OV-3.

### Claim 71 (depends on 51)

A method as claimed in claim 51, wherein the said synergistic lignan composition inhibits the growth of cancel cells of prostrate up to 98% at a concentration ranging from 30-100 μg/ml

### Claim 72 (depends on 71)

A method as claimed in claim 71, the prostrate cell lines inhibited are DU-145 and PC-3.

### Claim 73 (depends on 51)

A method as claimed in claim 51, wherein the said synergistic lignan composition is administered to the patient in combination with a pharmaceutically acceptable additive, carrier, diluent, solvent, filter, lubricant, excipient, binder, or stabilizer.

### Claim 74 (depends on 51)

A method as claimed in claim 51, wherein amount of synergistic composition administered is ranging from 10 to 500 mg/kg body weight for at least one dose per day.

### Claim 75 (depends on 51)

The method as claimed in claim 51, wherein, amount of synergistic lignan composition administered is preferably ranging from 50 to 350 mg/kg body weight.

### Claim 76

A method of treating a patient with cancer mainly breast, cervix, neuroblastoma, colon, liver, lung, mouth, ovary and prostate, said method comprising administering a pharmaceutically effective dosage of (−)-wikstromol or a composition containing (−)-woikstromol. to the patient.

### Claim 77 (depends on 76)

The method as claimed in claim 76, wherein the said composition inhibits the growth of cancer cells consisting of breast cells, cervix cells, neuroblastoma cells, colon cells, liver cell and lung cell up to 51%, 37%, 56%, 67%,46% and 56% respectively.

### Claim 78 (depends on 76)

The method as claimed in claim 76, wherein the cancer cell lines are selected from the group comprising of breast cells MCF-7 and ZR-75-1; cervix cell SiHa; neuroblastoma cells SKNMC and IMR-32; colon cells Colo-205, HT-29 and SW-620; liver cell Hep-2; and lung cell A-549.

### Claim 79 (depends on 76)

The method as claimed in claim 76 wherein the composition is used singly or in combination with pharmaceutically acceptable carriers.

### Claim 80 (depends on 76)

The method as claimed in claim 76 wherein the composition can be administered systematically and/or orally or any other suitable method.

### Claim 81 (depends on 76)

The method as claimed in claim 76 wherein the subjects are selected from animals or mammals preferably humans.

### Claim 82 (depends on 76)

The method as claimed in claim 76 wherein the amount of composition administered is ranging from 10 to 500 mg/kg body weight at least once in a day.

### Claim 83 (depends on 76)

The method as claimed in claim 76 wherein the amount of composition administered is preferably ranging from 75 to 300 mg/kg body weight at least once in a day.

### Claim 84 (depends on 76)

The method as claimed in claim 76 wherein the (−)-wikstromol is administered to the patient in combination with a pharmaceutically acceptable carriers additives, diluents, solvents, filters, lubricants, excipients, binders and stabilizers.

### Claim 85

A method of treating a patient with cancer mainly breast, cervix, neuroblastoma, colon, liver and lung, said method comprising administering a pharmaceutically effective dosage of (−)-Matairesinol or a composition containing (−)-Matairesinol to the patient.

### Claim 86 (depends on 85)

The method as claimed in claim 85, wherein the said composition inhibits the growth of cancer cells consisting of breast cells, cervix cells, neuroblastoma cells, colon cells, liver cell and lung cell up to 62%, 63%, 77%, 93%, 64% and 65% respectively.

### Claim 87 (depends on 85)

The method as claimed in claim 85, wherein the cancer cell lines are selected from the group comprising of breast cells MCF-7 and ZR-75-1; cervix cell SiHa;
neuroblastoma cells SKNMC and IMR-32; colon cells Colo-205, HT-29 and SW-620; liver cell Hep-2; and lung cell A-549.

### Claim 88 (depends on 85)

The method as claimed in claim 85 wherein (−)-Matairesinol is used singly or in combination with pharmaceutically acceptable carriers.

### Claim 89 (depends on 85)

The method as claimed in claim 85 wherein (−)-Matairesinol may be administered systematically or orally.

### Claim 90 (depends on 85)

The A method as claimed in claim 85 wherein the subjects are selected from animals or mammals preferably humans.

### Claim 91 (depends on 76)

The method as claimed in claim 76 wherein the amount of composition administered is ranging from 10 to 500 mg/kg body weight at least once in a day.

### Claim 92 (depends on 76)

The method as claimed in claim 76 wherein the amount of composition administered is preferably ranging from 75 to 300 mg/kg body weight at least once in a day.

### Claim 93 (depends on 85)

The method as claimed in claim 85 wherein the (−)-Matairesinol composition is administered to the patient in combination with a pharmaceutically acceptable carriers additives, diluents, solvents, filters, lubricants, excipients, binders and stabilisers.
